公开(公告)号：US20220387347A1

公开(公告)日：2022-12-08

申请号：US17576868

申请日：2022-01-14

申请人： GW Pharma Limited ,  Otsuka Pharmaceutical Co., Limited

发明人： Benjamin WHALLEY ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

IPC分类号： A61K31/05 ,  A61K36/185 ,  A61K31/352 ,  A61K31/045 ,  A61K31/353 ,  A61K45/06

摘要： This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

公开(公告)号：US20220395470A1

公开(公告)日：2022-12-15

申请号：US17585415

申请日：2022-01-26

申请人： GW Pharma Limited ,  Otsuka Pharmaceutical Co. Limited

发明人： Benjamin WHALLEY ,  Claire Williams ,  Gary Stephens

IPC分类号： A61K31/05 ,  A61K31/19 ,  A61K31/4015 ,  A61K31/352 ,  A61K36/00 ,  A61K31/515 ,  A61K45/06

摘要： The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

公开(公告)号：US20180228751A1

公开(公告)日：2018-08-16

申请号：US15751563

申请日：2016-07-29

申请人： GW PHARMA LIMITED

发明人： Colin STOTT ,  Nicholas JONES ,  Robin WILLIAMS ,  Benjamin WHALLEY

IPC分类号： A61K31/192 ,  A61P25/08 ,  A61K36/185 ,  A61K31/05 ,  A61K45/06

摘要： The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy. In one embodiment the CBDA is used in the treatment of generalised seizures, preferably tonic-clonic seizures. Preferably the CBDA used is in the form of a botanical drug substance in which the CBDA content is greater than 60%, and most preferably, it is a highly purified extract of cannabis such that the CBDA is present at greater than 95%, through 96% and 97% to most preferably, greater than 98% of the total extract (w/w) and the other components of the extract are characterised. In particular the cannabinoids tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA) have been substantially removed. Alternatively, the CBDA may be synthetically produced.